Sherie A Dowsett
Overview
Explore the profile of Sherie A Dowsett including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
1138
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wessels A, Dennehy E, Dowsett S, Dickson S, Hendrix S
Neurol Clin Pract
. 2023 Mar;
13(2):e200127.
PMID: 36891463
Purpose Of Review: To provide relevant background of the Integrated Alzheimer's Disease Rating Scale (iADRS), with examples, to assist the reader with the interpretation of iADRS findings from the TRAILBLAZER-ALZ...
2.
Wessels A, Belger M, Johnston J, Yu Y, Rentz D, Dowsett S, et al.
J Alzheimers Dis
. 2022 Jun;
88(2):577-588.
PMID: 35694928
Background: The integrated Alzheimer's Disease Rating Scale (iADRS) is a validated cognitive/functional composite that effectively captures cognitive and functional decline over a broad spectrum of disease. The clinical meaningfulness of...
3.
Reuter U, Krege J, Lombard L, Gomez Valderas E, Krikke-Workel J, Dell-Agnello G, et al.
Cephalalgia
. 2021 Oct;
42(1):20-30.
PMID: 34644189
Background: A significant proportion of triptan users exhibit an insufficient response or inadequate tolerability to a triptan, and some may develop a contraindication. Lasmiditan, a selective 5-HT receptor agonist, may...
4.
Ashina M, Reuter U, Smith T, Krikke-Workel J, Klise S, Bragg S, et al.
Cephalalgia
. 2021 Feb;
41(3):294-304.
PMID: 33541117
Background: We present findings from the multicenter, double-blind Phase 3 study, CENTURION. This study was designed to assess the efficacy of and consistency of response to lasmiditan in the acute...
5.
Doty E, Krege J, Pohl G, Case M, Dowsett S, Tepper S
Headache
. 2020 Jul;
60(8):1793-1796.
PMID: 32700321
No abstract available.
6.
Smith T, Krege J, Rathmann S, Dowsett S, Hake A, Nery E, et al.
Neurol Ther
. 2020 May;
9(2):459-471.
PMID: 32447545
Introduction: Migraine is associated with substantial functional impairment and affects many aspects of daily life. Methods: Using data from SAMURAI and SPARTAN (double-blind, placebo-controlled, phase 3 studies) and GLADIATOR (an...
7.
Tepper S, Silberstein S, Rosen N, Lipton R, Dennehy E, Dowsett S, et al.
Headache
. 2019 Dec;
60(1):178-189.
PMID: 31792964
Objective: To review the published findings relevant to migraine and driving performance, with an intent to encourage discussion on research which may broaden understanding in this area and help educate...
8.
Shen Loo L, Plato B, Turner I, Case M, Raskin J, Dowsett S, et al.
BMC Neurol
. 2019 Aug;
19(1):191.
PMID: 31409292
Background: We studied the efficacy and safety of a second dose of lasmiditan for acute treatment of migraine. Methods: SAMURAI and SPARTAN were double-blind, placebo-controlled Phase 3 studies in which...
9.
Goadsby P, Dodick D, Leone M, Bardos J, Oakes T, Millen B, et al.
N Engl J Med
. 2019 Jul;
381(2):132-141.
PMID: 31291515
Background: Episodic cluster headache is a disabling neurologic disorder that is characterized by daily headache attacks that occur over periods of weeks or months. Galcanezumab, a humanized monoclonal antibody to...
10.
Krege J, Rizzoli P, Liffick E, Doty E, Dowsett S, Wang J, et al.
Cephalalgia
. 2019 Jun;
39(8):957-966.
PMID: 31166697
Background: We assessed the safety profile of lasmiditan, a selective 5-HT receptor agonist without vasoconstrictive activity being developed as an acute therapy for migraine. Methods: SAMURAI and SPARTAN were Phase...